Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world’s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world’s biomedical information to enable the most efficient analysis at scale.
Explore Velsera in Action.
Dive into our latest resources to stay ahead in biomedical research and innovation. Whether you’re looking for insights, expert webinars, or the latest tools to enhance your research, Velsera’s got it all.
Our resources are designed to empower you with the knowledge and capabilities to push the boundaries of what’s possible. Explore now and see how Velsera is driving the future of precision medicine.
Check out what Velsera has to offer here: https://lnkd.in/gJTEpACr
If you’re interested in learning more about any of our tools with an expert team member, request a demo here: https://lnkd.in/gShhf_Vh#EraofVelsera#DrugDiscovery#PrecisionMedicine
Seven Bridges is thrilled to continue our next chapter as a part of Velsera!
At Velsera, we'll continue our journey of innovation and excellence, offering solutions to advance scientific research. Follow us on Velsera's LinkedIn page to stay connected with our latest news and developments.
See the Seven Bridges platform in action with Velsera here: https://lnkd.in/g6pKUjM3#EraofVelsera#DrugDiscovery#PrecisionMedicine
Struggling to push the boundaries of personalized medicine and immunotherapy? Neoantigens might be the breakthrough you've been searching for.
Julie Gil, PhD, Principal Solution Scientist at Velsera, discusses the cutting-edge world of neoantigen discovery—an innovation transforming cancer treatment and personalized medicine. In this presentation, Julie reveals how advances in bioinformatics, machine learning, and genomics are unlocking new possibilities for patient care.
Explore the future of immunotherapy! Watch Julie’s insightful presentation on-demand now and discover how neoantigens could hold the key to more effective, personalized treatments.
https://lnkd.in/grW258ZA#PersonalizedMedicine#Neoantigens#EraOfVelsera
Seeking deeper insights beyond traditional transcriptomics? Unlock new research potential with Velsera!
Don't miss our upcoming webinar on single-cell and spatial transcriptomics capabilities in biomedical research. Tatjana Kovacevic, PhD Kovacevic will discuss how these innovative methods are enhancing our understanding of tissue cell diversity, developmental processes, and tumor heterogeneity.
#EraOfVelsera#DrugDiscovery#Webinar#Research
It’s not too late to register for our upcoming webinar on single-cell and spatial transcriptomics in biomedical research. Join Dr. Tatjana Kovacevic, PhD as she discusses how single-cell RNA sequencing and spatial transcriptomics are revolutionizing our understanding of tissue cell diversity, developmental processes, and tumor heterogeneity.
🔸 Date: August 1st, 2024
🔸 Time: 8 AM PST/11 AM EST/5 PM CEST
Register here: https://lnkd.in/g9ag6SFe#Webinar#Research#SingleCell#BiomedicalResearch#Discovery
We are thrilled to announce our collaboration with Flywheel.io and the Center for Data Driven Discovery in Biomedicine at Children's Hospital of Philadelphia to advance the frontier of biomedical research.
This initiative, conducted through the NIH-wide INCLUDE Project, combines Velsera's CAVATICA platform with Flywheel Enterprise capabilities, enabling seamless, secure, and scalable cloud-based research and data analysis like never before.
Our pilot effort, focused on pediatric brain MRI imaging, has already shown promising results. By integrating imaging features analyzed on Flywheel with genomic variants identified on CAVATICA, we've demonstrated enhanced prediction of clinical outcomes.
But this is just the beginning. Together, we're empowering researchers to break down silos, collaborate effectively, and accelerate discovery.
Join us in celebrating this milestone in biomedical research and stay tuned for more updates as we continue to push the boundaries of innovation in healthcare!
Read the full press release: https://lnkd.in/eX6hDXVk#PrecisionMedicine#Discovery#Imaging#Genomics#EraofVelsera
Velsera's first year: Successes and looking to the future
One year ago, Velsera was launched as the unification of three leading companies offering enterprise-grade bioinformatics on a connected cloud platform (Seven Bridges), clinical genomics interpretation and reporting (Pierian), and lab automation and quality control (UgenTec).
The Velsera vision to power the health ecosystem with data and insights made actionable by AI is being realized! Highlights of the #EraofVelsera so far:
🔸8 of the top 10 biopharma companies in the world and leading national governments trust our platforms to support their discovery and diagnostics programs.
🔸Our Clinical Genomics Workspace (CGW) platform delivers hundreds of clinical reports every day to empower healthcare providers and patients to make critical diagnostic and treatment decisions.
🔸More than 1 million patients are covered through datasets that thousands of researchers around the world can access within the Seven Bridges platform.
🔸Velsera platforms were cited or mentioned in 116 journal articles, and members of our Seven Bridges team were authors on five of those publications.
🔸CGW introduced ground-breaking clinical evidence review capabilities that learn users’ reporting preferences and remember past decisions. The platform’s combination of expertly curated evidence, dynamic interpretations and adaptive behavior speeds up the signing out of reports and generates smarter clinical interpretation.
🔸In May, we hosted our inaugural Diagnostics & Discovery Summit, featuring leading experts tackling cutting-edge topics: AI applications, multi-omics, large-scale data engineering, universal inherited cancer testing and more. It was a captivating forum for collaboration and thought leadership among researchers, clinicians, and industry partners — the multidisciplinary stakeholders in the future of precision medicine.
🔸Strategic partnerships were announced with top precision medicine and healthcare computing companies, including NVIDIA, Solaris Health, and Arima Genomics.
Why it matters: Velsera is the engine driving new discoveries and sparking exponential advances for human health. And what we do matters because the partnerships we forge and the insights we deliver bring about positive impact for patients.
We thank and applaud our customers and partners, from large pharmaceutical and biotech companies to emerging innovators in oncology R&D to major governmental, academic and institutional partners. And we offer sincere appreciation to our expert team around the globe who have worked so hard to push Velsera forward – supporting their colleagues and our customers with unflagging dedication. You are the best!
#PrecisionMedicine#Genomics#anniversary
